Bridgeway Capital Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $286K | Sell |
126,000
-180,624
| -59% | -$410K | 0.01% | 876 |
|
|
2025
Q1 | $195K | Sell |
306,624
-25,000
| -8% | -$15.9K | ﹤0.01% | 933 |
|
|
2024
Q4 | $342K | Sell |
331,624
-25,000
| -7% | -$25.8K | 0.01% | 895 |
|
|
2024
Q3 | $421K | Sell |
356,624
-12,500
| -3% | -$14.8K | 0.01% | 902 |
|
|
2024
Q2 | $450K | Sell |
369,124
-74,100
| -17% | -$90.4K | 0.01% | 882 |
|
|
2024
Q1 | $966K | Buy |
443,224
+8,700
| +2% | +$19K | 0.02% | 751 |
|
|
2023
Q4 | $674K | Buy |
434,524
+62,400
| +17% | +$96.7K | 0.01% | 866 |
|
|
2023
Q3 | $480K | Buy |
372,124
+134,100
| +56% | +$173K | 0.01% | 884 |
|
|
2023
Q2 | $409K | Buy |
238,024
+62,024
| +35% | +$107K | 0.01% | 960 |
|
|
2023
Q1 | $266K | Hold |
176,000
| – | – | 0.01% | 1047 |
|
|
2022
Q4 | $282K | Hold |
176,000
| – | – | 0.01% | 1003 |
|
|
2022
Q3 | $255K | Buy |
+176,000
| New | +$255K | 0.01% | 1087 |
|